title: VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
abstract: OBJECTIVE
  This prospective study was undertaken to evaluate the efficacy of combination chemotherapy with alternating cycles of vincristine, doxorubicin, and dexamethasone (VAD) and prednisone, vindesine, carmustine, and cyclophosphamide (PECC) in poor-risk multiple myeloma (MM).
  
  
  METHODS
  Forty-four patients were previously untreated; 36 had been pretreated with an alkylating agent-containing regimen and had refractory or relapsed MM. All previously untreated patients had a high tumor burden at inclusion (stage III according to the Durie and Salmon classification). Logistic regression and the Cox proportional hazards models were used to assess the association between patient characteristics and response rate and survival, respectively.
  
  
  RESULTS
  The overall response rate was 68% for previously untreated patients, compared with 54% for previously treated patients (P = .16). The median survival time for all patients was 28 months: 53 months in previously untreated patients, and 18 months in previously treated patients. Univariate analysis showed that the predictive factors that had a significant affect on survival in the newly diagnosed patients were age, therapeutic response to VAD-PECC, low pretreatment Karnofsky score, high baseline serum beta 2-microglobulin (beta 2M) level, bone marrow impairment, and renal insufficiency at the start of treatment. When these parameters were used as continuous variables in multivariate analysis, three were found to correlate with survival: serum beta 2M, followed by therapeutic response and Karnofsky score. In the previously treated group, only Karnofsky score entered the Cox model.
  
  
  CONCLUSIONS
  These results indicate that combination VAD-PECC chemotherapy is an effective treatment that results in high response rates and long-term survival in advanced MM.
authors.affiliation: Department of Hematology/Oncology, Hôpital Bretonneau, Tours, France.
authors.forename: M
authors.initials: M
authors.lastname: Delain
authors.forename: C
authors.initials: C
authors.lastname: Linassier
authors.forename: C
authors.initials: C
authors.lastname: Petitdidier
authors.forename: P
authors.initials: P
authors.lastname: Goupille
authors.forename: F
authors.initials: F
authors.lastname: Luthier
authors.forename: M
authors.initials: M
authors.lastname: Combe
authors.forename: M
authors.initials: M
authors.lastname: Reisenleiter
authors.forename: L
authors.initials: L
authors.lastname: Benboubker
authors.forename: J P
authors.initials: JP
authors.lastname: Lamagnère
authors.forename: P
authors.initials: P
authors.lastname: Colombat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D012044:Regression Analysis; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D014751:Vindesine; D002330:Carmustine; D011241:Prednisone